#ECMO Market

[market-insider]

Extracorporeal Membrane Oxygenation (ECMO) Machine Market: A Holistic Approach to Market Size, Share, and Growth Opportunities

The global extracorporeal membrane oxygenation machine market size is expected to reach USD 445.7 million by 2030, according to a new report by Grand View Research, Inc., registering a CAGR of 5.4% during the forecast period. The market is primarily driven by the increasing incidence of cardiopulmonary & respiratory diseases and technological advancements in the field of ECMO procedures. Cardiovascular disease is one of the leading causes of death globally.

Extracorporeal Membrane Oxygenation Machine Market Report Highlights      

North America accounted for the largest share in 2022 owing to favorable reimbursement policies, the presence of key players, and government initiatives    

By component, the oxygenators segment accounted for the largest market size owing to its high cost and usage  

By modality, the veno-arterial segment accounted for the largest market size and is also expected to grow at the fastest rate during the forecast period  

By patient type, the adult segment is growing at a rapid pace during the forecast period owing to the rising incidence of cardiac and pulmonary diseases  

By application, the respiratory segment held the largest market size in 2022 and is also expected to grow at the fastest rate  

Major players in the market are focusing on technological collaboration and product launches  

For More Details or Sample Copy please visit link @: Extracorporeal Membrane Oxygenation Machine Market Report

According to the WHO, 17.9 million people died from cardiovascular diseases in 2019  In addition, according to the Extracorporeal Life Support Organization, a total of 45,035 patients globally suffered from respiratory illnesses in 2016. Furthermore, increasing awareness about ECMO procedures coupled with various government initiatives is further propelling the growth.

The increasing survival rate of ECMO machine supported surgery for cardiac and respiratory patients is also augmenting the market growth. Applications of ECMO machine procedures have increased over the years. ECMO machine was traditionally used in cases of circulatory or respiratory failure, its applications have expanded to use as rescue therapy for post-organ transplantation and sepsis and in cases of heart failure.

The ECMO machine use has been rising gradually worldwide, owing to its benefits such as artificial lungs for the patients and growing awareness about its use. Moreover, increasing healthcare expenditure by government and private agencies in order to improve healthcare facilities is also aiding in the growth of the market. According to the American Heart Association, medical expenditure related to CVDs is expected to reach USD 960 billion by 2030 from USD 320 billion in 2011.

[industryforecastnews]

ECMO Machine Market Size To Reach $445.7 Million By 2030

Extracorporeal Membrane Oxygenation Machine Market Growth & Trends

The global extracorporeal membrane oxygenation machine market size is anticipated to reach to reach USD 445.7 million by 2030, expanding at a CAGR of 5.5% from 2024 to 2030, based on a new report by Grand View Research, Inc. This growth can be attributed to the rising prevalence of cardiopulmonary and respiratory diseases, increasing adoption of ECMO machines in hospitals, and technological advancements in ECMO machines. The market expansion is also driven by the need for advanced life support technologies like ECMO machines, which are becoming increasingly necessary in treating patients with severe or life-threatening cardiac or pulmonary conditions.

The rising prevalence of cardiovascular and respiratory diseases. Diseases such as coronary heart disease, cerebrovascular disease, rheumatic and congenital heart diseases, respiratory diseases like acute respiratory distress syndrome (ARDS), and chronic obstructive pulmonary diseases are leading causes of death worldwide. For instance, according to the World Heart Federation, approximately 18.6 million people die annually from cardiovascular diseases. Additionally, about 190,000 Americans are diagnosed with ARDS annually in the U.S. Such an increasing prevalence of cardiovascular and respiratory diseases has boosted the demand for ECMO machines, driving the market growth.

In addition, the increasing rate of technical improvement is increasing the usage of products. It is easier to transfer critically ill patients now as machine parts like hollow pumps and oxygenators are smaller. Moreover, introducing technologically advanced components, such as improved rotary pumps, dual-lumen cannulas, innovative oxygenators, and new cannulation approaches, is anticipated to ease the use of ECMO machines. For instance, in 2022, Inspira Technologies OXY B.H.N. Ltd. recently introduced the "Liby" System, an advanced life support system used to treat patients with life-threatening heart and lung failure. Similar advancements and the introduction of new products are expected to drive market growth in the coming years.

Request a free sample copy or view report summary: Extracorporeal Membrane Oxygenation Machine Market Report

Extracorporeal Membrane Oxygenation Machine Market Report Highlights

In 2023, the oxygenators segment accounted for the largest market share. This can be attributed due to prevalence of diseases like coronary heart disease and chronic obstructive pulmonary disease (COPD) continues to rise, the demand for advanced life support technologies like ECMO machines increases, driving the growth of the oxygenators segment.

The veno-arterial segment dominated the modality segment of ECMO machine market in 2023. This growth can be attributed due to high usage of veno-arterial ECMO in treating patients with cardiac arrest, where it assists with algorithm life support strategies to restore blood circulation. Additionally, the increasing incidence of chronic obstructive pulmonary disease (COPD) is also a key driver of this market segment.

The respiratory segment dominated the application segment in 2023 due to the high prevalence of respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and acute respiratory distress syndrome (ARDS), which are leading causes of death worldwide, necessitate advanced life support technologies like ECMO machines.

The adult patient segment dominated the patient type segment in 2023 due to the prevalent incidence of heart and lung-related issues necessitating life-saving interventions.

The North American region held the largest share of the market in 2023 due to key industry players, consistent product launches, government backing for quality healthcare, advanced healthcare infrastructure, and favorable reimbursement policies.

Market players adopt several strategic initiatives to increase the product reach and improve availability in diverse geographic areas.

Extracorporeal Membrane Oxygenation Machine Market Segmentation

Grand View Research has segmented the global extracorporeal membrane oxygenation machine market on the basis of component, modality, application, patient type and region:

Extracorporeal Membrane Oxygenation (ECMO) Machine Component Outlook (Revenue, USD Million, 2018 - 2030)

Pumps

Oxygenator

Controllers

Cannula

Accessories

Extracorporeal Membrane Oxygenation (ECMO) Machine Modality Outlook (Revenue, USD Million, 2018 - 2030)

Veno-Arterial

Veno-Venous

Arterio-Venous

Extracorporeal Membrane Oxygenation (ECMO) Machine Patient Type Outlook (Revenue, USD Million, 2018 - 2030)

Neonates

Pediatric

Adult

Extracorporeal Membrane Oxygenation (ECMO) Machine Application Outlook (Revenue, USD Million, 2018 - 2030)

Respiratory

Neonates

Pediatric

Adult

Cardiac

Neonates

Pediatric

Adult

ECPR

Neonates

Pediatric

Adult

Extracorporeal Membrane Oxygenation (ECMO) Machine Region Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players of Extracorporeal Membrane Oxygenation Machine Market

Medtronic Plc

Maquet Holding

Microport Scientific Corporation

Terumo Cardiovascular System Corporation

Medos Medizintechnik

Nipro Medical Corporation

LivaNova PLC

CytoSorbents Corporation

EUROSETS S.R.L

Browse Full Report: Extracorporeal Membrane Oxygenation Machine Market Report

[health-views-updates]

Cardiac Assist Devices Market: 2024 Analysis, Size, Key Players, Industry Research Trends & Forecast 2032

The global cardiac assist devices market is expected to grow significantly over the next decade, reaching a market size of USD 2.24 billion by 2032. The market, which was valued at USD 1.25 billion in 2023, is anticipated to expand at a compound annual growth rate (CAGR) of 6.06% from 2024 to 2032. The increasing prevalence of heart failure, advancements in medical technology, and rising demand for innovative cardiovascular solutions are key drivers of this growth.

Cardiac assist devices (CADs) are mechanical pumps that help support heart function and blood flow in patients with weakened hearts. These devices are used in patients with severe heart failure, particularly those awaiting heart transplants or who are unable to receive one. They play a critical role in reducing the burden of cardiovascular diseases by improving patient survival rates and quality of life.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases: Cardiovascular diseases (CVDs), including heart failure, continue to be the leading cause of death globally. According to the World Health Organization (WHO), an estimated 17.9 million people die each year from CVDs. The rising incidence of heart failure, fueled by factors such as an aging population, sedentary lifestyles, and increasing rates of obesity and diabetes, is driving demand for cardiac assist devices.

Technological Advancements in Cardiac Care: Continuous advancements in medical technology have led to the development of more efficient and miniaturized cardiac assist devices. Innovations in left ventricular assist devices (LVADs), total artificial hearts (TAHs), and extracorporeal membrane oxygenation (ECMO) systems have significantly improved device performance, durability, and patient outcomes. These technological advancements are expected to further boost the adoption of cardiac assist devices.

Growing Demand for Bridge-to-Transplant and Destination Therapy: Cardiac assist devices are increasingly being used as both a bridge-to-transplant therapy and as a long-term destination therapy for patients who are ineligible for heart transplants. With the growing demand for heart transplants and the limited availability of donor organs, cardiac assist devices provide a life-saving option for patients awaiting transplants. Furthermore, the rise in elderly populations globally, who may not be suitable candidates for transplantation, is also driving demand for long-term device solutions.

Increasing Healthcare Expenditure and Infrastructure Development: The expansion of healthcare infrastructure, particularly in emerging markets, is creating new opportunities for the cardiac assist devices market. As healthcare systems improve and healthcare expenditure rises, more hospitals and clinics are adopting advanced cardiovascular treatments, including the use of assistive devices for heart failure patients.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/4472 

Challenges and Opportunities

While the cardiac assist devices market shows strong growth potential, several challenges remain. High costs associated with the devices, the complexity of surgeries, and the risk of complications such as infection, bleeding, and device malfunction may limit the market's expansion. However, ongoing research into improving device safety, patient management, and reducing costs is expected to mitigate some of these challenges.

The development of next-generation cardiac assist devices that offer enhanced durability, reduced risk of complications, and easier implantation techniques presents a significant opportunity for market players. Additionally, increasing investments in clinical trials and research on new therapeutic approaches to heart failure treatment are likely to spur further market growth.

Regional Insights

North America dominates the global cardiac assist devices market, driven by high rates of cardiovascular disease, advanced healthcare infrastructure, and a well-established reimbursement system. The United States, in particular, has a strong presence of key market players and a high adoption rate of innovative cardiovascular treatments.

Europe follows closely, with growing healthcare investments and increasing awareness of heart failure management driving market growth. Countries such as Germany, the United Kingdom, and France are leading contributors in the region.

The Asia-Pacific region is expected to witness the highest growth rate over the forecast period. Factors such as rising healthcare expenditure, improving access to medical technologies, and a large population burdened by cardiovascular diseases are contributing to this growth. Additionally, increasing government initiatives aimed at improving cardiac care infrastructure in countries like China and India are expected to fuel market expansion.

Future Outlook

As the global burden of heart failure continues to rise, the demand for cardiac assist devices will grow, fueled by technological advancements and a greater focus on improving patient outcomes. With a projected CAGR of 6.06% from 2024 to 2032, the cardiac assist devices market will play an increasingly vital role in the management of end-stage heart failure and other cardiovascular conditions.

In conclusion, the cardiac assist devices market is expected to experience steady growth over the next decade, rising from USD 1.25 billion in 2023 to USD 2.24 billion by 2032. As cardiovascular diseases remain a leading health concern globally, the market for innovative and life-saving cardiac assist devices will continue to expand, providing critical support for heart failure patients worldwide.

Other Trending Reports

Functional Endoscopic Sinus Surgery Market Size

Artificial Intelligence in Healthcare Market Size

Radiotherapy Market Size

Nicotine Replacement Therapy Market Size

[pranalip]

Extracorporeal Membrane Oxygenation Machine Market In-depth Market Studies and Forecast 2024-2033 | Global Insight Services

The global extracorporeal membrane oxygenation machine market was valued at USD 541 million in 2021 and it is anticipated to grow further up to USD 862 million by 2031, at a CAGR of 4.8% during the forecast period.

Extracorporeal Membrane Oxygenation Machines assist patients who have trouble giving their body’s heart and lungs enough oxygen. For many patients, it serves as a life support system since it supports their respiratory systems. For those with life-threatening illnesses, good respiratory function is essential, which is why the Extracorporeal Membrane Oxygenation Machine is available to them. The market for extracorporeal membrane oxygenators is expanding because of the rising incidence of cardiovascular disorders, respiratory issues, and the quickening adoption of ECMO. The global market for ECMO is being boosted by both ECMO usage and an increase in ECMO centers.

To Know More@ https://www.globalinsightservices.com/reports/extracorporeal-membrane-oxygenation-machine-market

Market Trends and Drivers

The increasing adoption of ECMO in lung transplantation procedures is boosting the growth of the market. In recent years, there has been a surge in lung transplantation, particularly for the treatment of advanced lung conditions such as cystic fibrosis, interstitial lung disease, and chronic obstructive pulmonary disease (COPD). The use of ECMO equipment in lung transplant operations has grown dramatically over time in the treatment of patients with advanced lung disease. Primary Graft Dysfunction (PGD) following lung transplantation is the most typical reason for using ECMO. PGD is a syndrome that develops within the first 72 hours of a lung transplant. Numerous studies have demonstrated promising results in relation to the use of ECMO as a bridging approach as well as therapy for individuals suffering from PGD after transplant thanks to substantial technological advancements. In the upcoming years, it is anticipated that ECMO use would increase even more due to the rising prevalence of lung illnesses worldwide.

Request Sample@ https://www.globalinsightservices.com/request-sample/GIS10285

Research Objectives

Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region

Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling

Identify factors influencing market growth and challenges, opportunities, drivers and restraints

Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates

Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities

Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market

To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.

Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives

Request Customization@ https://www.globalinsightservices.com/request-customization/GIS10285

Global Extracorporeal Membrane Oxygenation Machine Market Segmentation

By Component

Pumps

Oxygenators

Controllers

Cannula

Accessories

By Modality

Veno-Arterial

Veno-Venous

Arterio-Venous

By Patient Type

Neonates

Pediatric

Adult

By Application

Respiratory

Cardiac

ECPR

Major Players of the Global Extracorporeal Membrane Oxygenation Machine Market

The key players studied in the market are FRESENIUS MEDICAL CARE AG & CO. KGAA, GETINGE GROUP, MEDTRONIC PLC, MICROPORT, TERUMO CARDIOVASCULAR SYSTEMS CORPORATION, NIPRO CORPORATION, LIVANOVA PLC, EUROSETS S.R.L., ORIGEN BIOMEDICAL, INC., CYTOSORBENTS CORPORATION, ABIOMED, BRAILE BIOMÉDICA, SPECTRUM MEDICAL, HAEMONETICS, XENIOS AG, among others.

COVID-19 Impact

In 2020, the COVID-19 pandemic had a negative impact on the global economy and caused a number of difficulties for patients and clinical healthcare providers. Because of the stringent lockdowns that the governments of the majority of countries applied, COVID-19 has also had an impact on different levels of the value chain. Newer packaging guidelines and country-imposed lockout procedures have also impacted the turnaround time for the delivery of goods and services. All of these elements have a detrimental effect on the production and supply chain of digital X-ray equipment.

Buy your copy here@ https://www.globalinsightservices.com/checkout/single_user/GIS10285

Research Scope

Scope – Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Contact Us:

Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: info@globalinsightservices.com Phone: +1-833-761-1700 Website: https://www.globalinsightservices.com

About Global Insight Services:

lobal Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

[uptothetrendblogs]

Global Acute Respiratory Distress Syndrome (ARDS) Market

Global Acute Respiratory Distress Syndrome (ARDS) Market Seen Soaring ~8% Growth to Reach USD ~1,987 Million  by 2032, Projects Univdatos Market Insights

According to a new report by Univdatos Market Insights, the global acute respiratory distress syndrome (ARDS) market is expected to reach around USD 1,987  Million in 2032 by growing at a CAGR of 8%. ARDS can be described as a severe case of inflammation in the lungs that occurs suddenly and results in the development of respiratory failure. This is generally associated with various causes like pneumonia, sepsis, trauma as well as inhaling injuries. ARDS is defined as a lung injury that compromises the normal ability to oxygenate blood, has severe hypoxemia in patients receiving mechanical ventilation, and has a high mortality rate. The process here is often characterized by endothelial and epithelial injury with leakage of fluid into the air space, impaired oxygenation, and inflammation.

Demand Globally

Such treatments are needed globally since ARDS is a concern of humanity with potentially devastating consequences on public health. Every year, tens of thousands of patients present with ARDS, especially in the intensive care units as this type of disease occurs most frequently. It adds tremendous cost implications to health institutions because of longer hospitalization, mechanical ventilation, and complications attached to the condition. These findings underline the need for more effective therapies, as well as for an early and improved understanding of disease progression that can affect the outcomes of those with ARDS.

Unlock The Insights of This Strategic Report – https://univdatos.com/report/acute-respiratory-distress-syndrome-ards-market/get-a-free-sample-form.php?product_id=62149

Treatment Cost

The level of payment required for the treatment of ARDS is adjustable and includes not only direct medical costs such as hospitalization, transportation to the ICU, mechanical ventilation, and drugs but indirect costs associated with productivity loss and rehabilitation as well. The total cost of the interventions continues to be an essential concern in the management of patients as well as in policy formulation because cost usually determines the practicality of methods that have demonstrable positive effects on patient results The emphasis on cost-efficient therapies has continued because the practical implication of a treatment procedure also depends on its impact on cost since shorter lengths of stay and overall health care usage are desirable.

Application

Modern management of ARDS entails a conservative approach in the sense that no specific therapy targets the disease directly, but our main line of approach includes supportive care, utilization of low tidal volumes to the extent where mechanical ventilation is necessary, prone positioning to enhance oxygenation and pharmacological intervention whose purpose is to decrease the inflammatory response and enhance lung function. Some medications that can be used are cortical steroids, neuromuscular blocking agents, and investigational therapies that target certain particular biochemical pathways.

The treatment of ARDS is still being researched even in clinical trials to find new ways for instance, stem cell therapy for lung regeneration, ECMO for removing toxic substances from the lung, and immune-modulating agents that target the underlying cause of the condition. Moreover, improvements in the supportive care approaches have also involved steps in the early identification and intervention for other associated problems like ventilator-acquired pneumonia and sepsis to further improve the patient’s outcomes.

Adult Current Asthma Prevalence by State or Territory (2021)

Recent Developments/Awareness Programs:- Several key players and governments are rapidly adopting strategic alliances, such as partnerships, or awareness programs for the treatment:-

Fisher & Paykel Healthcare Limited launched its new Optiflow+ nasal high-flow therapy system in January 2021. This system is designed to provide respiratory support to patients with Acute Respiratory Distress Syndrome (ARDS) and other respiratory conditions.

March 2024: the FDA approved Medtronic's Evolut FX+ TAVR system for treating severe aortic stenosis. The system maintains the benefits of the legacy Evolut TAVR platform and facilitates coronary access.

Unlock The Insights of This Strategic Report – https://univdatos.com/report/acute-respiratory-distress-syndrome-ards-market/get-a-free-sample-form.php?product_id=62149

Conclusion

Therefore, owing to the rapidly evolving and technologically advanced nature of the ARDS market and the persisting need for effective treatment and management solutions for such a fatal disease, it is evident that the global market offers further research and development data. In more than 3 decades of ARDS research, there has been substantial progress in identifying aspects of the disease pathophysiology and enhancing supportive care, although cost-effective, specific anti-inflammatory treatments are still lacking. This paper emphasized the role and importance of pharmaceutical firms, academic centers, and healthcare organizations effectively working together to improve the current level of care delivered to patients with ARDS, to reduce the impact of this disease on societies across the world. Furthering the realization of treatment prospects of ARDS through individualized medication remains an unbounded possibility toward the betterment of survival of development sufferers of the syndrome.

Key Offerings of the Report

Market Size, Trends, & Forecast by Revenue | 2024−2032F.

Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities

Market Segmentation – A detailed analysis by Treatment and End-User

Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Contact:

UnivDatos Market Insights

contact@univdatos.com 

+91 7838604911

[adityarana1687-blog]

Extracorporeal Membrane Oxygenation Machine Market To Reach $445.7 Million By 2030

The global extracorporeal membrane oxygenation machine market size is anticipated to reach to reach USD 445.7 million by 2030, expanding at a CAGR of 5.5% from 2024 to 2030, based on a new report by Grand View Research, Inc. This growth can be attributed to the rising prevalence of cardiopulmonary and respiratory diseases, increasing adoption of ECMO machines in hospitals, and technological advancements in ECMO machines. The market expansion is also driven by the need for advanced life support technologies like ECMO machines, which are becoming increasingly necessary in treating patients with severe or life-threatening cardiac or pulmonary conditions.

The rising prevalence of cardiovascular and respiratory diseases. Diseases such as coronary heart disease, cerebrovascular disease, rheumatic and congenital heart diseases, respiratory diseases like acute respiratory distress syndrome (ARDS), and chronic obstructive pulmonary diseases are leading causes of death worldwide. For instance, according to the World Heart Federation, approximately 18.6 million people die annually from cardiovascular diseases. Additionally , about 190,000 Americans are diagnosed with ARDS annually in the U.S. Such an increasing prevalence of cardiovascular and respiratory diseases has boosted the demand for ECMO machines, driving the market growth.

In addition, the increasing rate of technical improvement is increasing the usage of products. It is easier to transfer critically ill patients now as machine parts like hollow pumps and oxygenators are smaller. Moreover, introducing technologically advanced components, such as improved rotary pumps, dual-lumen cannulas, innovative oxygenators, and new cannulation approaches, is anticipated to ease the use of ECMO machines. For instance, in 2022, Inspira Technologies OXY B.H.N. Ltd. recently introduced the "Liby" System, an advanced life support system used to treat patients with life-threatening heart and lung failure. Similar advancements and the introduction of new products are expected to drive market growth in the coming years.

Request a free sample copy or view report summary: Extracorporeal Membrane Oxygenation Machine Market Report

Extracorporeal Membrane Oxygenation Machine Market Report Highlights

In 2023, the oxygenators segment accounted for the largest market share. This can be attributed due to prevalence of diseases like coronary heart disease and chronic obstructive pulmonary disease (COPD) continues to rise, the demand for advanced life support technologies like ECMO machines increases, driving the growth of the oxygenators segment.

The veno-arterial segment dominated the modality segment of ECMO machine market in 2023. This growth can be attributed due to high usage of veno-arterial ECMO in treating patients with cardiac arrest, where it assists with algorithm life support strategies to restore blood circulation. Additionally, the increasing incidence of chronic obstructive pulmonary disease (COPD) is also a key driver of this market segment.

The respiratory segment dominated the application segment in 2023 due to the high prevalence of respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and acute respiratory distress syndrome (ARDS), which are leading causes of death worldwide, necessitate advanced life support technologies like ECMO machines.

The adult patient segment dominated the patient type segment in 2023 due to the prevalent incidence of heart and lung-related issues necessitating life-saving interventions.

The North American region held the largest share of the market in 2023 due to key industry players, consistent product launches, government backing for quality healthcare, advanced healthcare infrastructure, and favorable reimbursement policies.

Market players adopt several strategic initiatives to increase the product reach and improve availability in diverse geographic areas.

Extracorporeal Membrane Oxygenation Machine Market Segmentation

Grand View Research has segmented the global extracorporeal membrane oxygenation machine market on the basis of component, modality, application, patient type and region:

Extracorporeal Membrane Oxygenation (ECMO) Machine Component Outlook (Revenue, USD Million, 2018 - 2030)

Pumps

Oxygenator

Controllers

Cannula

Accessories

Extracorporeal Membrane Oxygenation (ECMO) Machine Modality Outlook (Revenue, USD Million, 2018 - 2030)

Veno-Arterial

Veno-Venous

Arterio-Venous

Extracorporeal Membrane Oxygenation (ECMO) Machine Patient Type Outlook (Revenue, USD Million, 2018 - 2030)

Neonates

Pediatric

Adult

Extracorporeal Membrane Oxygenation (ECMO) Machine Application Outlook (Revenue, USD Million, 2018 - 2030)

Respiratory

Neonates

Pediatric

Adult

Cardiac

Neonates

Pediatric

Adult

ECPR

Neonates

Pediatric

Adult

Extracorporeal Membrane Oxygenation (ECMO) Machine Region Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players of Extracorporeal Membrane Oxygenation Machine Market

Medtronic Plc

Maquet Holding

Microport Scientific Corporation

Terumo Cardiovascular System Corporation

Medos Medizintechnik

Nipro Medical Corporation

LivaNova PLC

CytoSorbents Corporation

EUROSETS S.R.L

[market-insider]

Extracorporeal Membrane Oxygenation Machine | Exploring Opportunities and Challenges

The global extracorporeal membrane oxygenation machine market size is anticipated to reach to reach USD 445.7 million by 2030, expanding at a CAGR of 5.5% from 2024 to 2030, based on a new report by Grand View Research, Inc. This growth can be attributed to the rising prevalence of cardiopulmonary and respiratory diseases, increasing adoption of ECMO machines in hospitals, and technological advancements in ECMO machines. The market expansion is also driven by the need for advanced life support technologies like ECMO machines, which are becoming increasingly necessary in treating patients with severe or life-threatening cardiac or pulmonary conditions.

Extracorporeal Membrane Oxygenation Machine Market Report Highlights

In 2023, the oxygenators segment accounted for the largest market share. This can be attributed due to prevalence of diseases like coronary heart disease and chronic obstructive pulmonary disease (COPD) continues to rise, the demand for advanced life support technologies like ECMO machines increases, driving the growth of the oxygenators segment.

The veno-arterial segment dominated the modality segment of ECMO machine market in 2023. This growth can be attributed due to high usage of veno-arterial ECMO in treating patients with cardiac arrest, where it assists with algorithm life support strategies to restore blood circulation. Additionally, the increasing incidence of chronic obstructive pulmonary disease (COPD) is also a key driver of this market segment.

The respiratory segment dominated the application segment in 2023 due to the high prevalence of respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and acute respiratory distress syndrome (ARDS), which are leading causes of death worldwide, necessitate advanced life support technologies like ECMO machines.

The adult patient segment dominated the patient type segment in 2023 due to the prevalent incidence of heart and lung-related issues necessitating life-saving interventions.

The North American region held the largest share of the market in 2023 due to key industry players, consistent product launches, government backing for quality healthcare, advanced healthcare infrastructure, and favorable reimbursement policies.

Market players adopt several strategic initiatives to increase the product reach and improve availability in diverse geographic areas.

For More Details or Sample Copy please visit link @: Extracorporeal Membrane Oxygenation Machine Market Report

The rising prevalence of cardiovascular and respiratory diseases. Diseases such as coronary heart disease, cerebrovascular disease, rheumatic and congenital heart diseases, respiratory diseases like acute respiratory distress syndrome (ARDS), and chronic obstructive pulmonary diseases are leading causes of death worldwide. For instance, according to the World Heart Federation, approximately 18.6 million people die annually from cardiovascular diseases. Additionally, about 190,000 Americans are diagnosed with ARDS annually in the U.S. Such an increasing prevalence of cardiovascular and respiratory diseases has boosted the demand for ECMO machines, driving the market growth.

In addition, the increasing rate of technical improvement is increasing the usage of products. It is easier to transfer critically ill patients now as machine parts like hollow pumps and oxygenators are smaller. Moreover, introducing technologically advanced components, such as improved rotary pumps, dual-lumen cannulas, innovative oxygenators, and new cannulation approaches, is anticipated to ease the use of ECMO machines. For instance, in 2022, Inspira Technologies OXY B.H.N. Ltd. recently introduced the "Liby" System, an advanced life support system used to treat patients with life-threatening heart and lung failure. Similar advancements and the introduction of new products are expected to drive market growth in the coming years.

[industryinsightsandanalysis]

Antithrombin Market Size, Trend, Analysis and Forecast (2021-2027)

The antithrombin market is anticipated to grow at a CAGR of approximately 5% during the forecast period. Antithrombin, a protein produced by the liver and present in blood, plays a crucial role in inhibiting blood clotting by inactivating thrombin. Deficiency in antithrombin can arise from conditions such as nephrotic syndrome, liver failure, severe trauma, metastatic tumors, and genetic mutations. Additionally, advancements in drug administration technology and an increase in blood clotting disorders are fueling market growth. Antithrombin deficiency heightens the risk of thromboembolism, which can lead to excessive bleeding during surgeries. Antithrombin III is commonly used for extracorporeal membrane oxygenation (ECMO) during cardiopulmonary bypass. According to the National Institutes of Health (NIH), approximately 310 million surgeries are performed annually in the U.S.

Market Segmentation by Application

The antithrombin market is segmented into therapeutic, research, and diagnostics. In 2020, the therapeutic segment is expected to experience significant growth, driven by the rising number of cardiac surgeries, ongoing drug research and development, and increasing prevalence of heart-related diseases such as atrial fibrillation and heart failure. The demand for antithrombin in therapeutic applications is on the rise, as antithrombic drugs and treatments are crucial for managing heart diseases. For example, the Centers for Disease Control and Prevention (CDC) estimates that 12.1 million people in the U.S. will have atrial fibrillation (AFib) by 2030.

For a comprehensive analysis of the market drivers, visit: https://univdatos.com/report/antithrombin-market/

Market Segmentation by Source

The antithrombin market is categorized into human, goat milk, and others. The goat milk segment is projected to see substantial growth due to its proven medical efficacy. Goat milk is a significant external source of antithrombin, capable of producing as much antithrombin in a year as 90,000 blood donations. Factors such as increasing cases of blood clotting, high blood pressure, high cholesterol, and cardiac surgeries are driving this market segment. Key market players are also launching new products to address antithrombin deficiency.

Market Segmentation by Dosage Form

The market is divided into lyophilized and liquid forms. The lyophilized segment held a significant market share and is expected to grow considerably, primarily due to its use in treating thrombin deficiency and coronary heart diseases (CAD). According to the CDC, around 18.2 million adults have coronary artery disease. Additionally, lyophilized antithrombin is used to treat venous thromboembolism (VTE) and peripheral artery diseases (PAD), serious yet preventable conditions that can cause disability and death. This segment is expected to see continued growth.

Regional Market Analysis

The report provides a comprehensive analysis of major regions, including North America (U.S., Canada, Rest of North America); Europe (Germany, U.K., France, Spain, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific); and the Rest of the World. In 2020, North America held a significant market share, driven by the high prevalence of heart disease, a large population, availability of skilled healthcare professionals, and major pharmaceutical companies. The region also sees a high incidence of blood clots, further contributing to market growth. According to the CDC, as many as 100,000 people in the U.S. die from blood clots each year, costing the nation up to $10 billion annually.

For a sample report, visit: https://univdatos.com/get-a-free-sample-form-php/?product_id=23070

Major Companies

Key players in the antithrombin market include Grifols S.A., Octapharma AG, LFB USA Inc., CSL Limited, Takeda Pharmaceuticals, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., and BDI Pharma Inc.

Contact Us:

UnivDatos Market Insights

Email - contact@univdatos.com

Contact Number - +1 9782263411

Website -www.univdatos.com

[rahulp3]

Key Segments Profiled in the Arterial Cannula Market Industry Survey

The Global Arterial Cannula Industry is on an upward trajectory, driven by the increasing demand for cardiovascular surgeries and interventions. A groundbreaking study by Future Market Insights (FMI) forecasts an impressive Compound Annual Growth Rate (CAGR) of 6.6% for the industry from 2023 to 2033. This positive outlook suggests the market will reach a remarkable valuation of US$40 billion by 2033, signifying a new era of advancements and innovation in medical technology.

The surge in demand for arterial cannulas is attributed to the escalating incidence of chronic diseases necessitating critical medical interventions. Procedures such as cardiopulmonary bypass surgery (CABG), dialysis, and Extracorporeal Membrane Oxygenation (ECMO) are becoming increasingly prevalent, driving the need for cutting-edge medical solutions. The Global Arterial Cannula Industry is set to play a pivotal role in meeting this growing demand, propelling itself into an era of unparalleled growth.

Request a Sample of this Report Now!https://www.futuremarketinsights.com/reports/sample/rep-gb-15945

[bhushans]

The Rise of Tech-Driven Therapies: Reshaping the Global Cardiopulmonary Bypass Systems market

The global Cardiopulmonary Bypass Systems market. According to a recent analysis, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.2% over the forecast period, from US$ 197.3 million in 2023 to US$ 270.9 million in 2033.

The forecasted growth in the Cardiopulmonary Bypass Systems market reflects the increasing demand for these devices driven by the rising costs associated with treating major illnesses, including cardiac disorders. Despite challenges such as unfavorable side effects resulting from bypass surgeries, the market is expected to benefit from rapid technological advancements and the growing number of surgical procedures.

Navigate Future Trends With a Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-5855

Supporting Heart Health: Cardiopulmonary Bypass Systems Play a Vital Role

The global cardiopulmonary bypass system market is experiencing continued growth, driven by the increasing need for effective tools in cardiac surgery. Cardiopulmonary bypass systems play a critical role in open-heart surgery by temporarily taking over the functions of the heart and lungs, allowing surgeons to operate on a still heart.

Market Growth Fueled by Multiple Factors:

Several factors are contributing to the growth of the cardiopulmonary bypass system market:

Increased Focus on Cardiac Care: Rising healthcare expenditure directed towards combating heart disease, a leading global health concern, is creating a greater demand for advanced cardiac surgical procedures.

Technological Advancements: The market is continuously evolving with the development of innovative bypass systems. Roller pumps, for example, are gaining traction due to their affordability, ease of use, and reliable flow management.

Expanding Surgical Needs: The growing number of lung transplant procedures, particularly en-bloc double-lung transplants, is driving the demand for cardiopulmonary bypass systems to support these complex surgeries.

Key Takeaways:

The global cardiopulmonary bypass system market is expected to reach US$270.9 million by 2033, reflecting a rise from US$197.3 million in 2023.

This growth is projected at a steady compound annual growth rate (CAGR) of 3.2% throughout the forecast period.

Rising healthcare spending on cardiac procedures and advancements in technology are key drivers for market expansion.

The Cardiopulmonary Bypass System Market:

Minnetronix Inc.

Transonic

MAQUET Holding B.V. & Co. KG.

Getinge AB

Terumo Corporation

MicroPort Scientific Corporation

Xenios AG

Nipro Corporation

Eurosets Srl

OriGen Biomedical

Thoratec Corporation

Tianjin Medical

Olympus Corporation

Haemonetics Corporation

Some Recent Developments in the Cardiopulmonary Bypass System Market are:

In June 2014, Sorin Group celebrated the delivery of its 10,000th heart-lung machine (S5 heart-lung machine) to Brigham and Women’s Hospital, Boston, MA, USA. Thuse achieved an exciting milestone that reflects the tremendous trust and collaborative partnership with their customers worldwide.

In October 2021, MicroPort acquired 100% of the equity held by existing shareholders of Hemovent GmbH. Hemovent specializes in the development of ground-breaking Extracorporeal Life Support (ECLS) systems.

In February 2022, Getinge acquired 100% of the equity interest in Talis Clinical LLC, a US-based leading innovator of High Acuity cloud-based software solutions. Talis Clinical’s offer is designed to support and document care throughout the general and cardiac perioperative care process, but also through labor and delivery episodes and critical care support, including ECMO Therapy.

In April 2022, LivaNova initiated the targeted commercial launch of Essenz™. Patient Monitor for cardiopulmonary bypass procedures. The transformative monitoring system uses a patient-tailored approach to improve clinical efficiency and quality of patient care during cardiopulmonary bypass (CPB) procedures.

In January 2021, Eurosets announced the full commercial release (out of the USA) of its novel ECMOlife system for Extracorporeal Life Support (ECLS). ECMOlife expands Eurosets’ portfolio to temporarily support patients in different therapeutic areas, including Extracorporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS).

Key Segments Profiled in the Cardiopulmonary Bypass System Industry Survey Report:

By Product Type:

Conventional

Mini

By Modality:

Standalone

Portable

By End User:

Hospitals

Ambulatory Surgical Centers

Cardiac Research Centers

By Region:

North America

Latin America

Asia Pacific

The Middle East and Africa

Europe

[envil22100]

Data Bridge Market Research analyses that the global cardiopulmonary bypass accessory equipment market, which was USD 15.93 billion in 2023, is expected to reach USD 25.01 billion by 2031, at a CAGR of 5.8% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.